159938 医药
已收盘 11-05 15:00:00
资讯
新帖
简况
礼邦医药-B(09637)11月5日斥资约11.54万港元回购6600股
智通财经 · 11-05 22:03
礼邦医药-B(09637)11月5日斥资约11.54万港元回购6600股
东方证券股份有限公司(DFZQ)增持劲方医药-B29.96万股 每股作价约23.44港元
同花顺 · 11-05 19:28
东方证券股份有限公司(DFZQ)增持劲方医药-B29.96万股 每股作价约23.44港元
电子医药双热！私募10月调研图谱出炉：高毅、淡水泉、聚鸣频频现身，源杰科技、胜宏科技最受关注
私募一线 · 11-05 17:24
电子医药双热！私募10月调研图谱出炉：高毅、淡水泉、聚鸣频频现身，源杰科技、胜宏科技最受关注
11月5日山外山涨5.21%，圆信永丰医药健康A基金重仓该股
证券之星 · 11-05 16:55
11月5日山外山涨5.21%，圆信永丰医药健康A基金重仓该股
迪哲医药：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会
同花顺 · 11-05 16:21
迪哲医药：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会
迪哲医药(688192.SH)：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会
智通财经 · 11-05 16:17
迪哲医药(688192.SH)：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会
礼邦医药-B盘中涨超5%
同花顺 · 11-05 15:27
礼邦医药-B盘中涨超5%
医药股午后继续走高 中国生物制药涨超7%百济神州涨超6%
新浪港股 · 11-05 13:48
医药股午后继续走高 中国生物制药涨超7%百济神州涨超6%
港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年
智通财经 · 11-05 10:47
港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年
劲方医药-B盘中涨超12%，GFH276获临床许可及基金增持回购
同花顺 · 11-05 10:33
劲方医药-B盘中涨超12%，GFH276获临床许可及基金增持回购
迪哲医药：11月4日融资买入6455.94万元，融资融券余额2.87亿元
同花顺 · 11-05 09:48
迪哲医药：11月4日融资买入6455.94万元，融资融券余额2.87亿元
迪哲医药（688192）11月4日主力资金净卖出403.78万元
证券之星 · 11-05 08:32
迪哲医药（688192）11月4日主力资金净卖出403.78万元
股市必读：大参林新发布《大参林医药集团股份有限公司关于控股股东股份解除质押的公告》
证券之星 · 11-05 01:57
股市必读：大参林新发布《大参林医药集团股份有限公司关于控股股东股份解除质押的公告》
礼邦医药-B11月4日耗资约124.85万港元回购7.41万股
同花顺 · 11-04 22:03
礼邦医药-B11月4日耗资约124.85万港元回购7.41万股
汇添富基金增持劲方医药-B29.96万股 每股作价约23.44港元
同花顺 · 11-04 19:29
汇添富基金增持劲方医药-B29.96万股 每股作价约23.44港元
汇添富基金增持劲方医药-B(02595)29.96万股 每股作价约23.44港元
智通财经 · 11-04 19:19
汇添富基金增持劲方医药-B(02595)29.96万股 每股作价约23.44港元
劲方医药10月回购114.88万股H股存入库存，已发行股份降至3.49亿股
同花顺 · 11-04 18:07
劲方医药10月回购114.88万股H股存入库存，已发行股份降至3.49亿股
11月4日键凯科技涨6.30%，圆信永丰医药健康A基金重仓该股
证券之星 · 11-04 17:16
11月4日键凯科技涨6.30%，圆信永丰医药健康A基金重仓该股
迪哲医药涨8.35%，东海证券一个月前给出“买入”评级
证券之星 · 11-04 17:10
迪哲医药涨8.35%，东海证券一个月前给出“买入”评级
11月4日热景生物涨6.56%，富国医药创新股票A基金重仓该股
证券之星 · 11-04 17:07
11月4日热景生物涨6.56%，富国医药创新股票A基金重仓该股
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.663,"timestamp":1793862210000,"preClose":0.647,"halted":0,"volume":73688700,"delay":0,"changeRate":0.0247,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.016,"latestTime":"11-05 15:00:00","open":0.646,"high":0.663,"low":0.646,"amount":48492800,"amplitude":0.0263,"askPrice":0.663,"askSize":7285,"bidPrice":0.662,"bidSize":4874,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793928600000},"marketStatusCode":5,"adr":0,"adjPreClose":0.647,"symbolType":"fund","openAndCloseTimeList":[[1793842200000,1793849400000],[1793854800000,1793862000000]],"highLimit":0.712,"lowLimit":0.582,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.269968,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2681966079","title":"礼邦医药-B(09637)11月5日斥资约11.54万港元回购6600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681966079","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681966079?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:03","pubTimestamp":1793887391,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B(09637)发布公告，于2026年11月5日该公司斥资约11.54万港元回购6600股，回购价格为每股17.29至17.64港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09637","BK1515","09939","159938","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681021781","title":"东方证券股份有限公司(DFZQ)增持劲方医药-B29.96万股 每股作价约23.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681021781","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681021781?lang=zh_cn&edition=full","pubTime":"2026-11-05 19:28","pubTimestamp":1793878080,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，10月30日，东方证券股份有限公司(DFZQ)增持劲方医药-B(02595)29.96万股，每股作价23.4445港元，总金额约为702.40万港元。增持后最新持股数目约为1777.48万股，持股 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261105/c681518892.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261105/c681518892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0028","BK0183","600958","BK0276","159938","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681047519","title":"电子医药双热！私募10月调研图谱出炉：高毅、淡水泉、聚鸣频频现身，源杰科技、胜宏科技最受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2681047519","media":"私募一线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681047519?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:24","pubTimestamp":1793870640,"startTime":"0","endTime":"0","summary":"近期，A股私募调研活跃度持续上行。整体来看，电子和医药生物成为最受关注的两大板块，百亿私募与中小私募均在加大调研投入力度。当月共有130家私募调研次数不少于10次，其中前十名机构的调研次数均超过50次。在百亿私募阵营中，除高毅资产外，淡水泉和聚鸣投资也跻身机构调研次数前十，分别调研63次和54次。此外，还有9家百亿私募当月调研次数在20次及以上，包括上海常春藤私募、姚泾河私募、重阳投资、景林资产等。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/original/2026-11-05/doc-inixsrry6074350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","LU1934453819.USD","LU1481107354.HKD","159938","688498","02476","LU0469268626.HKD","LU0164865239.USD","300476","LU1979443071.USD","BK1170","LU0531971595.HKD","BK0214","BK1574","BK1515","BK1161","LU0871576103.HKD","LU0039217434.USD","SGXZ49509284.SGD","LU0164880469.USD","BK0197","SGXZ81163826.USD","LU1808992512.USD","LU0149721374.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681442510","title":"11月5日山外山涨5.21%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681442510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681442510?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:55","pubTimestamp":1793868914,"startTime":"0","endTime":"0","summary":"证券之星消息，11月5日山外山涨5.21%，收盘报10.9元，换手率3.37%，成交量15.07万手，成交额1.63亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.82亿元，最新净值1.8553，较上一交易日上涨1.54%，近一年下跌5.89%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500029609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688410","BK1161","BK1574","BK1515","BK0251","150219","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681041548","title":"迪哲医药：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2681041548","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681041548?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:21","pubTimestamp":1793866860,"startTime":"0","endTime":"0","summary":"迪哲医药(688192.SH)发布公告，公司将于12月12日至15日在美国新奥尔良举办的第68届美国血液学会(ASH)年会上，公布血液肿瘤管线的8项最新临床研究成果，包含3项口头报告和5项壁报展示，涉及 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261105/c681506022.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261105/c681506022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681049058","title":"迪哲医药(688192.SH)：血液瘤产品多项研究成果入选第68届美国血液学会(ASH)年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2681049058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681049058?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:17","pubTimestamp":1793866675,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司将于12月12日至15日在美国新奥尔良举办的第68届美国血液学会年会上，公布血液肿瘤管线的8项最新临床研究成果，包含3项口头报告和5项壁报展示，涉及公司血液瘤领域的三大核心产品——高选择性JAK1抑制剂高瑞哲、LYN/BTK双靶点抑制剂比瑞替尼以及新一代EZH1/2双靶点小分子抑制剂GW5282。此次大会上高瑞哲共有5项最新临床研究进展入选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","BK1574","ASH","BK0239","159938","BK1161","BK1515","LU2463526074.USD","688192","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681504596","title":"礼邦医药-B盘中涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681504596","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681504596?lang=zh_cn&edition=full","pubTime":"2026-11-05 15:27","pubTimestamp":1793863620,"startTime":"0","endTime":"0","summary":"11月5日，礼邦医药-B(09637.HK)盘中涨超5%，截至15时4分，涨5.40%，报18.340港元/股，成交额1623.33万港元。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261105/c681500877.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261105/c681500877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681142100","title":"医药股午后继续走高 中国生物制药涨超7%百济神州涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681142100","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681142100?lang=zh_cn&edition=full","pubTime":"2026-11-05 13:48","pubTimestamp":1793857680,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端医药股午后继续走高，创新药、CRO概念领衔。截至发稿，中国生物制药（01177）上7.18%，报5.52港元；百济神州（06160）上涨6.13%，报245.80港元；康方生物（09926）上涨4.85%，报86.50港元；信达生物（01801）上涨3.65%，报88.15港元；科伦博泰生物（06990）上涨2.89%，报455.20港元；药明康德（02359）上涨1.72%，报201.20港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-05/doc-inixsfae6194220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ08YT58.USD","BK1161","LU0588546209.SGD","BK1515","LU1719994722.HKD","BK1191","BK1500","LU0828237510.HKD","KURE","LU1303224171.USD","LU1969619763.USD","BK1588","BK0239","BK4585","LU1770034418.SGD","IE00BZ08YS42.EUR","LU2328871848.SGD","ONC","BK4139","06160","BK4588","HK0000165453.HKD","09939","LU1251922891.USD","LU0307460666.USD","688235","159938","BK1521","IE00BZ08YR35.GBP","BK1583","BK4526","LU0228659784.USD","01177","BK1574","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015969","title":"港股异动 | 医药股继续走强 中生制药斩获70亿美元BD领涨 前三季BD出海接近去年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681015969?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:47","pubTimestamp":1793846861,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，医药股今早继续走高，创新药、CRO概念领衔。中国生物制药11月4日盘后公告，与跨国药企勃林格殷格翰就下一代肿瘤疗法达成重磅对外授权，覆盖6个创新药临床前项目。公司可获3.58亿美元首付款，潜在总额最高达70亿美元，刷新公司BD交易金额纪录。东方证券指出，从医药整体来看，2026年前三季度营收同比增长1.4%，归母净利润同比增长11.6%，扣非归母净利润同比增长18.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0828237510.HKD","LU0650527681.SGD","BK4585","HK0000165453.HKD","LU0228659784.USD","LU2097828631.EUR","BK1161","BK4588","BK1588","LU0463099449.HKD","LU2097828474.EUR","LU2097828557.USD","IE00BZ08YT58.USD","BK1583","LU1188198961.HKD","LU1969619763.USD","LU2488822045.USD","IE00BZ08YR35.GBP","159938","BK1521","LU0607220059.USD","LU2097828714.EUR","LU2328871848.SGD","LU1251922891.USD","BK1191","BK1574","09939","01177","06990","LU0326950275.SGD","LU0196878994.USD","BK1500","BK1589","KCAI","LU2242644610.SGD","LU1770034418.SGD","LU0594300179.USD","06160","LU1831875114.USD","VXUS","LU1719994722.HKD","LU2097828805.USD","LU0588546209.SGD","01477","LU0244354667.USD","01801","BK1515","LU1303224171.USD","KURE","LU0149534421.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681001534","title":"劲方医药-B盘中涨超12%，GFH276获临床许可及基金增持回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2681001534","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681001534?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:33","pubTimestamp":1793845980,"startTime":"0","endTime":"0","summary":"11月5日，劲方医药-B(02595.HK)盘中涨超12%，截至10时29分，涨12.63%，报24.080港元/股，成交额3878.66万港元。消息面上，11月4日，香港联交所最新数据显示，10月30日汇添富基金增持公司29. ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261105/c681491728.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261105/c681491728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681301336","title":"迪哲医药：11月4日融资买入6455.94万元，融资融券余额2.87亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681301336","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681301336?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:48","pubTimestamp":1793843280,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日，迪哲医药（688192）融资买入6455.94万元，融资偿还3643.29万元，融资净买入2812.65万元，融资余额2.82亿元。融券方面，当日融券卖出6066.0股，融券偿还2700.0股，融 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261105/c681488636.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261105/c681488636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681097518","title":"迪哲医药（688192）11月4日主力资金净卖出403.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681097518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681097518?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:32","pubTimestamp":1793838728,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月4日收盘，迪哲医药报收于64.1元，上涨8.35%，换手率2.0%，成交量9.24万手，成交额5.7亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入6455.94万元，融资偿还3643.29万元，融资净买入2812.65万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500009906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","BK1161","688192","BK0239","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681929069","title":"股市必读：大参林新发布《大参林医药集团股份有限公司关于控股股东股份解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681929069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681929069?lang=zh_cn&edition=full","pubTime":"2026-11-05 01:57","pubTimestamp":1793815069,"startTime":"0","endTime":"0","summary":"公司公告汇总大参林医药集团股份有限公司关于控股股东股份解除质押的公告大参林医药集团股份有限公司于2026年11月4日发布公告，控股股东之一柯康保先生将其持有的25,500,000股公司股份解除质押，解除质押股份占其持股总数的14.31%，占公司总股本的2.16%。截至公告日，公司控股股东及其一致行动人合计持有公司股份706,668,982股，占公司总股本的59.87%，累计质押股份53,072,320股，占其所持股份比例7.51%，占公司总股本比例4.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500003640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603233","BK1574","09939","BK0114","BK0209","BK1161","159938","BK0185","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680105754","title":"礼邦医药-B11月4日耗资约124.85万港元回购7.41万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680105754","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680105754?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:03","pubTimestamp":1793800980,"startTime":"0","endTime":"0","summary":"礼邦医药-B(09637)公布，2026年11月4日耗资约124.85万港元回购7.41万股股份。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261104/c681476094.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261104/c681476094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680058662","title":"汇添富基金增持劲方医药-B29.96万股 每股作价约23.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680058662","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680058662?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:29","pubTimestamp":1793791740,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，10月30日，汇添富基金增持劲方医药-B(02595)29.96万股，每股作价23.4445港元，总金额约为702.40万港元。增持后最新持股数目为1777.48万股，持股比例为5.05%。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://fund.10jqka.com.cn/20261104/c681471050.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://fund.10jqka.com.cn/20261104/c681471050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680903064","title":"汇添富基金增持劲方医药-B(02595)29.96万股 每股作价约23.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680903064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680903064?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:19","pubTimestamp":1793791162,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月30日，汇添富基金增持劲方医药-B(02595)29.96万股，每股作价23.4445港元，总金额约为702.40万港元。增持后最新持股数目为1777.48万股，持股比例为5.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","02595","BK1574","09939","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680034812","title":"劲方医药10月回购114.88万股H股存入库存，已发行股份降至3.49亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680034812","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680034812?lang=zh_cn&edition=full","pubTime":"2026-11-04 18:07","pubTimestamp":1793786820,"startTime":"0","endTime":"0","summary":"11月4日，劲方医药科技(上海)股份有限公司向香港交易及结算所有限公司提交截至2026年10月31日止月份的证券变动月报表，呈交日期为2026年11月4日。2026年10月内，公司购回H股股份114.88万股 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261104/c681467826.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261104/c681467826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680488036","title":"11月4日键凯科技涨6.30%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680488036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680488036?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:16","pubTimestamp":1793783802,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日键凯科技涨6.30%，收盘报76.72元，换手率6.07%，成交量3.68万手，成交额2.73亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.82亿元，最新净值1.8272，较上一交易日下跌1.82%，近一年下跌8.52%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["150219","BK1515","09939","BK1161","159938","BK1574","BK0229","688356"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680036375","title":"迪哲医药涨8.35%，东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680036375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680036375?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:10","pubTimestamp":1793783456,"startTime":"0","endTime":"0","summary":"今日迪哲医药涨8.35%，收盘报64.1元。研报中预计公司2026-2028年实现归母净利润分别为-4.48/0.78/4.81亿元。公司研发快速推进，国际化价值兑现，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为67.43%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中金公司的张琎。迪哲医药个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","161027","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680705035","title":"11月4日热景生物涨6.56%，富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680705035","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680705035?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:07","pubTimestamp":1793783249,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日热景生物涨6.56%，收盘报69.0元，换手率3.29%，成交量3.05万手，成交额2.04亿元。重仓热景生物的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK0239","BK1161","09939","688068","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793904651081,"stockEarnings":[{"period":"1week","weight":0.0711},{"period":"1month","weight":0.0091},{"period":"3month","weight":-0.0163},{"period":"6month","weight":0.0376},{"period":"1year","weight":-0.0391},{"period":"ytd","weight":0.0216}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}